The U.S. FDA has expanded the indication for Glenmark’s RYALTRIS nasal spray to treat Seasonal Allergic Rhinitis in pediatric patients aged 6 to 11, in addition to adults and older children. The expansion is supported by Phase 3 data from 446 children showing meaningful improvement in nasal symptoms and good tolerability over a 14‑day period. The approval aligns with a broader clinical and market push, as 25% of children aged 6–11 were diagnosed with seasonal allergies in 2024 according to the CDC, underscoring the potential impact on sleep, wellbeing, and activity. Glenmark plans to move to direct U.S. commercialization effective April 1, 2026, enabling closer engagement with healthcare professionals and patients. RYALTRIS is a fixed‑dose nasal spray combining olopatadine hydrochloride and mometasone furoate, which was first approved in 2022 for adults and ages 12 and up, with this expansion broadening its pediatric use. Globally, RYALTRIS has a wide footprint across major markets and is now expanding further with new market launches in FY26, totaling 56 countries.